Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

21 May 2009

Hyperuricaemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients

A Karbowska, M Boratyńska, M Klinger

Ann Transplant 2009; 14(1): 33-33 :: ID: 880319

Abstract

Hyperuricaemia is common in renal transplant recipients treated with calcineurine inhibitors. Experimental studies suggest that uric acid induces glomerular hypertension, microvascular disease and renal interstitial fibrosis Hyperuricaemia is also an independent risk factor of cardiovascular complications. The mechanism by which uric acid injures renal allograft and cardiovascular system is still unclear. The aim of this study was to assess the influence of serum uric acid level on biomarkers of endothelial dysfunction and inflammation in renal allograft recipients. The study involved 78 adult renal transplant recipients (aged 19-70 years) with stable graft function (creatinine 0.7-1.4 mg/dl). The patients were transplanted between 2003 and 2006. Exclusion criteria were: abnormal renal function, proteinuria, diabetes mellitus, BMI above 30 and inflammation. The immunosuppressive protocol consisted of CsA or tacrolimus and azathioprine or mycophenolate mofetil and prednisone. The patients were divided into 2 groups: I - 48 patients with hyperuricaemia (uric acid 7.72±1.33 mg/dl) and II - 30 patients with normal uric acid level 5.48±0.92 mg/dl (control group). Markers of endothelial function and inflammation were assessed in both groups: plasma resistin level, CD146 and sVCAM-1. No significant differences were found in demographic data between both groups of patients with and without hyperuricaemia, such as age, gender, cause of renal failure, the number of HLA mismatches, DGF and number of episodes of acute rejection. The examined biomarkers were elevated in patients with hyperuricaemia. Resistin level was higher in hyperuricemic patients than in the control group (7.15±2.42 ng/ml vs. 6.29±2.76 ng/ml), and was higher in women (7.83 ng/ml) than in men (6.58 ng/ml). Also sVCAM-1 was significantly higher in hyperuricemic patients (1126±371ng/ml) when compared to patients with normal uric acid level (955±269 ng/ml) P<0.03. Resistin level correlated significantly with sVCAM-1 (P<0.01). CD146 was elevated in patients with hyperuricaemia (389.7±150 ug/ml). Hyperuricaemia mediates endothelial dysfunction and inflammation and may contribute to chronic allograft injury and cardiovascular events in renal allograft recipients.

Keywords: Kidney Transplantation

Add Comment 0 Comments

In Press

Case report  

Tongue Carcinoma in Immunosuppressed Patients After Liver and Kidney Transplantation: A Case Series

Ann Transplant In Press; DOI: 10.12659/AOT.951715  

Original article  

Prevalence and Risk Factors of Hepatic Steatosis in Kidney Transplant Recipients

Ann Transplant In Press; DOI: 10.12659/AOT.952251  

Original article  

The Anatomical Landscape of Living Donor Livers: A 101-Case Retrospective Single-Center Study in Indonesia ...

Ann Transplant In Press; DOI: 10.12659/AOT.952031  

Original article  

Decreased Ventilation Duration and ICU Stay Associated With Early Percutaneous Dilatational Tracheostomy Af...

Ann Transplant In Press; DOI: 10.12659/AOT.953143  

Most Viewed Current Articles

24 Aug 2021 : Review article   20,545

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

29 Dec 2021 : Original article   16,641

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

05 Apr 2022 : Original article   15,898

Impact of Statins on Hepatocellular Carcinoma Recurrence After Living-Donor Liver Transplantation

DOI :10.12659/AOT.935604

Ann Transplant 2022; 27:e935604

22 Nov 2022 : Original article   15,796

Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipient...

DOI :10.12659/AOT.937988

Ann Transplant 2022; 27:e937988

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358